Harmony Biosciences (NASDAQ:HRMY) Research Coverage Started at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft initiated coverage on shares of Harmony Biosciences (NASDAQ:HRMY) in a research note released on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $55.00 target price on the stock.

A number of other research firms have also recently commented on HRMY. HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a research report on Monday, January 27th. Oppenheimer reissued an “outperform” rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Cantor Fitzgerald lifted their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Monday, January 13th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Trading Up 3.3 %

Shares of HRMY stock opened at $39.08 on Tuesday. The firm’s 50 day moving average price is $35.95 and its two-hundred day moving average price is $35.58. Harmony Biosciences has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80.

Insider Activity

In related news, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,452 shares of company stock valued at $2,831,679. 30.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Harmony Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of HRMY. SG Americas Securities LLC lifted its holdings in Harmony Biosciences by 244.4% in the 3rd quarter. SG Americas Securities LLC now owns 15,724 shares of the company’s stock valued at $629,000 after acquiring an additional 11,158 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in Harmony Biosciences by 15.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 11,300 shares of the company’s stock valued at $452,000 after acquiring an additional 1,500 shares during the last quarter. CWM LLC raised its holdings in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after buying an additional 775 shares during the period. Creative Planning acquired a new stake in Harmony Biosciences during the 3rd quarter worth about $246,000. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in Harmony Biosciences by 20.8% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 54,274 shares of the company’s stock worth $2,171,000 after buying an additional 9,329 shares during the period. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.